This study is testing a new treatment called IOV-3001 in adults with advanced melanoma (a type of skin cancer that has spread or cannot be removed by surgery). IOV-3001 is given through an IV and is being studied to see how safe it is and what dose works best. You might be able to join if you are between 18 and 70 years old, have melanoma that is not in your eye, and your cancer has worsened after treatment with a PD-1/PD-L1 blocking antibody. This is the first time IOV-3001 is being given to people, and it will be given either before or after another treatment called lifileucel. The study aims to understand its safety within 30 days.

Study design

This is a Phase 1/2, open-label study, meaning both you and your doctors will know which treatment you are receiving. It plans to enroll 42 participants.

What's involved

You will receive IOV-3001 as a single IV infusion in a hospital setting. The study will assess safety and tolerability for up to 30 days.

Compensation

Not stated in the trial record.

Follow-up

The primary safety and tolerability endpoints are measured for up to 30 days after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.